In the Virus-Like Particle Translational Oncology Laboratory, Qizhi Cathy Yao, M.D., Ph.D. is developing non-infectious HIV virus-like particles (VLPs) as candidate HIV mucosal vaccines for both ...

Vaccine research has increasingly focused on virus-like particles (VLPs) due to their unique ability to mimic the structures of viruses without containing ...

The formation of VLP is depicted in Figure 1. Figure 1. The formation of a virus-like particle (VLP). Image Credit: Sino Biological Inc. To enable targeted drug research, Sino Biological has ...

The EC has authorised the marketing of Bavarian Nordic's Vimkunya chikungunya vaccine for individuals as young as 12 years ...

More information: Limei Wang et al, Nipah virus: epidemiology, pathogenesis, treatment, and prevention, Frontiers of Medicine (2024). DOI: 10.1007/s11684-024-1078-2 Provided by Higher Education Press ...

ProBioGen has expanded its protein and viral vector manufacturing capabilities at its Berlin headquarters, reinforcing its ...

The following is a summary of "Impact of HBsAg reduction via siRNA treatment on natural and vaccine (BRII-179)-induced ...

that compared the safety and immunogenicity of a single intramuscular dose of Vimkunya (n=2559), a virus-like particle chikungunya vaccine, with placebo (n=424) in healthy participants 12 to 64 ...

COPENHAGEN, Denmark, February 28, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the European Commission has granted marketing authorization in Europe for VIMKUNYA ® for active ...